Liftstream is an executive search recruitment company in the life sciences sector
The UK has been seriously tackling the issue of diversity in the senior ranks of British business. The Davies Review, led by the charismatic but challenging Lord Mervyn Davies, pushed UK boards to get 25% of women on the boards of FTSE 100 companies. This triggered concerted action on the part of the nominated companies because they would be publicly measured, and reported.
The New Year brings a period of reflection, what will you change in the year ahead and how will you do it? There are some clear ways in which the effectiveness of the board can be improved by the way in which the nominations and governance committee discharge their responsibilities. Here we listed 5 resolutions for an effective nominations committee. Click the following links to read detailed articles on each recommendation.
SV Life Sciences (SVLS), a life sciences venture capital firm with offices in Boston, London and San Francisco, has appointed Joshua Resnick as Partner. Based in Boston, Resnick joins SVLS’ biotech investment team which partners with experienced entrepreneurs and accomplished management teams.
The incredible challenge faced by corporations today in protecting data from cyber-attacks is ever evolving. The frequency and sophistication of cyber-attacks are testing CEOs, executive teams and perhaps more acutely, the Board. The Board of Directors is clearly responsible for risk oversight, and ‘Cyber-Risk’ is another form of corporate risk that they have to address. As part of their risk management responsibilities, the board should be defining and understanding the level of risk their company is exposed to and ensuring they are taking the appropriate measures to manage the risk through the correct processes and structures.
Valeant Pharmaceuticals is a very aggressive acquirer of companies and assets. The Canadian company has most recently purchased the rights to an asset from AstraZeneca in the area of psoriasis. The drug, brodalumab, was previously partnered with Amgen but the company exited the agreement from AstraZeneca earlier this year upon concerns of suicidal thoughts in patients enrolled in trials, allowing AZ to find a new partner for the late-stage asset.
Previously names Cell Therapeutics now CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) have appointment Bruce Seeley as Executive Vice President and Chief Commercial Officer, reporting to James Bianco, M.D., CTI BioPharma’s President and Chief Executive Officer. Seeley joins CTI BioPharma at the beginning of August 2015 and will serve on the executive leadership team, assuming responsibility for CTI BioPharma’s commercial organization worldwide – including sales, marketing, commercial operations, medical affairs and supply chain.